Showing results (171-180 of 277) with videos related to
Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway AlterationsElio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.Biorxiv : the Preprint Server for Biology|February 27, 2026
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancerXin Cheng, Changli Qian, Erica Holdridge, et al.Cancer Chemotherapy and Pharmacology|October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumorsKhanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2025
Molecular characterization of NUT carcinoma: a report from the NUT carcinoma registryJustin J Kim, Sara A Walton, Navin R Mahadevan, et al.Gynecologic Oncology|January 11, 2024
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trialClaire F Friedman, Anishka D'Souza, Diana Bello Roufai, et al.Nature Communications|May 4, 2026
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancerXin Cheng, Yadong Zhang, Changli Qian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumorsLeena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, et al.Cancer Cell|May 30, 2006
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapiesHongbin Ji, Danan Li, Liang Chen, et al.Pageof 28